Atorvastatin: Balancing LDL Reduction, Cardiovascular Prophylaxis, and Metabolic Risk in High-Risk Patients Within a Socioeconomic Context

Cardiovascular disease is a leading cause of death worldwide and in the US (High LDL cholesterol is a major risk factor) Atorvastatin lowers LDL cholesterol by competitively inhibiting HMG-CoA reductase We analyzed scientific literature and clinical data: Our findings show that atorvastatin reduces LDL cholesterol by approximately 35-60% and significantly lowers the risk of heart attack and stroke. Higher doses are associated with adverse effects: Increased blood glucose levels, insulin resistance, increased risk of type 2 diabetes, and muscle-related symptoms Despite risks, atorvastatin is highly effective for patients with high cardiovascular risk Our findings highlight the importance of: Appropriate dosing, patient monitoring, and individualized treatment modalities Optimize Prescribing Practices: Implement regular clinical audits and promote guideline-based statin prescription for high-risk populations, ensuring equitable access and address disparities. Advance Personalized Medicine: Move towards individualized treatment strategies that incorporate shared decision-making, considering patient-specific risk factors, tolerance levels, and individual metabolic responses. Enhance Side Effect Management: Implement routine blood glucose monitoring for patients on high-dose statin therapy. For patients exhibiting intolerance, evaluate dosage adjustments or switching to alternative high-intensity statins. Promote Further Research: Investigate the long-term metabolic impacts of high-intensity statin use and explore the potential of combination therapies to achieve therapeutic goals with lower statin doses.